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Background: WHIM syndrome (WS), a rare congenital neutropenia due to mutations of the CXCR4 chemokine
receptor, is associated with Human Papillomavirus (HPV)-induced Warts, Hypogammaglobulinemia, bacterial
Infections and Myelokathexis. The long term follow up of eight patients highlights the clinical heterogeneity
of this disease as well as the main therapeutic approaches and remaining challenges in the light of the recent
development of new CXCR4 inhibitors.
Objective: This study aims to describe the natural history of WS based on a French cohort of 8 patients.
Methods: We have reviewed the clinical, biological and immunological features of patients with WS enrolled into
the French Severe Chronic Neutropenia Registry.
Results: We identified four pedigrees with WS comprised of eight patients and one foetus. Estimated incidence for
WS was of 0.23 per million births. Median age at the last visit was 29 years. Three pedigrees encompassing seven
patients and the fetus displayed autosomal dominant heterozygous mutations of the CXCR4 gene, while one
patient presented a wild-type CXCR4 gene. Two subjects exhibited congenital conotruncal heart malformations. In
addition to neutropenia and myelokathexis, all patients presented deep monocytopenia and lymphopenia. Seven
patients presented repeated bacterial Ears Nose Throat as well as severe bacterial infections that were curable with
antibiotics. Four patients with late onset prophylaxis developed chronic obstructive pulmonary disease (COPD). Two
patients reported atypical mycobacteria infections which in one case may have been responsible for one patient’s
death due to liver failure at the age of 40.6 years. HPV-related disease manifested in five subjects and progressed as
invasive vulvar carcinoma with a fatal course in one patient at the age of 39.5 years. In addition, two patients
developed T cell lymphoma skin cancer and basal cell carcinoma at the age of 38 and 65 years.
Conclusions: Continuous prophylactic anti-infective measures, when started in early childhood, seem to effectively
prevent further bacterial infections and the consequent development of COPD. Long-term follow up is needed to
evaluate the effect of early anti-HPV targeted prophylaxis on the development of skin and genital warts.
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In 1964, Zuelzer reported an exceptional congenital neu-
tropenia associated with hyperplasia of mature neutrophils
in the bone marrow (BM) – myelokathexis (retention of
white blood cells in the BM) [1]. Its acronym (WHIM)
derived from the manifestations of Human Papillomavirus
(HPV)-induced Warts, Hypogammaglobulinemia, and
bacterial Infections together with Myelokathexis [2]. A
marked lymphopenia, which affects both T- and B-
lymphocytes and NK cells, completes the picture. The
clinical onset and complications in WHIM syndrome
(WS) are more variable than originally suspected with the
notable exceptions of neutropenia and lymphopenia,
which are always observed in patients suffering from this
disorder [3]. WS is also genetically heterogenous. Most
patients present heterozygous autosomal dominant muta-
tions of the gene encoding for CXCR4, the receptor of the
CXCL12 chemokine (or Stromal cell Derived Factor-1)
[4], which notably regulates hematopoiesis and peripheral
trafficking of neutrophil and lymphocyte subsets. CXCR4
engagement by CXCL12 induces typical activation of Gαi
protein-dependent pathways. All CXCR4 mutations
described so far result in partial truncations of the recep-
tor’s carboxyl terminal tail (C-tail), with the exception of
the recently described missense non truncating E343K
mutation [5], and impair the desensitization process which
precludes further G-protein activation thus leading to
enhanced and prolonged responsiveness of CXCR4
mutants to CXCL12 (i.e. gain of function) [6]. Leukocytes
from the minority of patients who carry a wild-type (WT)
CXCR4 gene presented a similar pattern of aberrant
CXCL12/CXCR4 responses [4,7–9] consistent with a role
for these dysfunctions in the WS hematological defects
[10]. In support of this assumption, a new knock-in mouse
strain that harbors a WS-associated heterozygous muta-
tion of the CXCR4 gene exhibits striking parallels to the
major immunological features of WS (i.e. panleukopenia)
and is considered as a valuable model of the human syn-
drome [11].
An exhaustive literature review since the first de-
scription in 1964 identified 52 cases originating from
the United States, Japan or Europe (Additional file 1)
[1,2,4,5,9,12–43]. Recurrent infections may be quite se-
vere, but other presentations are more indolent while
the white blood cell count (WBC) appears to be affected
in a large range, from mild lympho-neutropenia to near
panleukopenia. Therefore, the therapeutic management
of these patients is diverse. Some patients have no
prophylactic therapy, while others may receive prophylac-
tic antibiotics or antiviral therapies such as Immunoglo-
bulins (Ig), Granulocyte macrophage colony-stimulating
factor (GMCSF), Granulocyte colony-stimulating factor
(GCSF) and eventually undergo hematopoietic stem cell
transplantation [30]. Recently, plerixafor (or AMD3100),a small synthetic antagonist of CXCR4 approved for BM
hematopoietic progenitor cells transplantation [44], has
been tested in WS patients and found to promote the
mobilization of neutrophils and lymphocytes to the per-
ipheral blood [31,45]. These studies provide the first
pharmacological evidence of the causal role of the gain
of CXCR4 function in WS-associated panleukopenia and
explain the rationale for the use of CXCL12/CXCR4
antagonists in the management of WS. Both the extreme
rarity of WS and its clinical heterogeneity prompted us
to analyze all cases identified in France through the na-
tional Severe Chronic Neutropenia Registry. We collected
the patients’ exhaustive clinical, hematological and bio-
logical features, as well as their family histories, and
performed the genetic and functional analyses of the
CXCR4 receptor.
Patients and methods
Organization of the French registry and data monitoring
All patients included in this study were registered in the
French Severe Chronic Neutropenia Registry. The regis-
try was created in 1993; since then, enrollment has been
prospective. We included all types of congenital neutro-
penia [46]. The registry received national certification in
the year 2008 by the French health authorities. Thirty-
five French pediatric hematology-oncology clinical units
participate in this registry. Data monitoring was based
on the review of medical records collected by a clinical
research associate who visited each center yearly, and
multiple sources ascertained the completeness of each
case. The patient or his legal guardians provided written
informed consent before being included in the registry.
Several reports of the registry are available elsewhere
[47-49].
We used the common definition of WS. Briefly, WS
was diagnosed in patients with both neutropenia (defined
by at least one absolute neutrophil count (ANC) below
1.5 G/L) and myelokathexis on the BM smear after cen-
tral review. In addition to this phenotype, we considered
CXCR4 mutations as diagnostic criteria. When available,
we screened patients for biological CXCR4 dysfunctions.
All these criteria were found in one patient (UPN 5592)
who presented no CXCR4 mutation and whose cyto-
logical findings have been previously reported [50]. The
patient UPN 5446 has been partially reported elsewhere
[51] as well as the functional studies from three indivi-
duals of the cohort (UPN 5592, UPN 5446 and UPN
5231) [7,8].
Phenotyping
We only analyzed routinely recorded parameters such as
auxologic status and major medical events requiring
medical management. Ig levels were analyzed according
to age and expressed as standard deviations (SD) [52].
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from the patients’ written medical history. We defined
severe infections as those that would be life threatening
without appropriate antibiotic or antifungal therapy and
that entail medical supervision or hospitalization. These
events were exhaustively registered in the medical
records. Minor infections were those for which patients
did not seek medical surveillance such as stomatological
or ear, nose and throat (ENT) infections. These events
were often omitted in the medical records. Warts were
considered as a WS manifestation when their number
was equal or superior to ten or when they presented as
genital condylomata acuminita. We performed HPV
genotyping for one case of skin warts and one case of
ano-genital warts following a Quantitative PCR on fro-
zen biopsies with HPV-specific primers.
CXCR4 gene testing
The patients or their parents gave their written informed
consent for genetic and functional testing. Genomic
DNA was extracted from blood with standard proce-
dures. The coding sequence and exon-intron boundaries
of the CXCR4 gene (encompassing two exons) were
amplified using the primers and PCR conditions
described elsewhere. PCR products were sequenced in
both directions with the ABI PRISM Big Dye Terminator
v1.1 Ready Reaction Cycle Sequencing kit (Applied
Biosystems) on an ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems). Sequences were analyzed with
the Seqscape software v2.2 (Applied Biosystems). We
numbered mutations as recommended by the Human
Genome Variation Society (http://www.hgvs.org/), using
the reference sequence NM_003467.2.
Functional evaluation of the CXCL12/CXCR4 axis
Studies aimed at investigating the functioning of CXCR4
and other chemokine receptors (CCR5, CCR7, CXCR7)
were performed as previously described [7,8].
Statistical analysis
Stata software version 10 was used for all statistical ana-
lyses. Lower and upper interquartile, and median values
depict the distribution of quantitative variables. Consid-
ering that we ascertained the completion of the enrol-
ment only from 1990 to 2006, we only took into
consideration the years 1990–2006 to calculate the epi-
demiological parameters. Our research extracted the
number of births per year in France (metropolitan areas
excluding Reunion Island, French Polynesia or French
Antilles) from the records of the Institut National de la
Statistique et des Etudes Economiques (www.insee.fr).
Incidence at birth was supposed to satisfy a Poisson dis-
tribution. For survival analysis the endpoints were death,
and the first episode of cancer. The period taken intoaccount was the time interval from birth to the first date
when the event was observed or to the last examination
when no event occurred. The Kaplan-Meier method
was used to estimate survival rates. The cut-off date
was February 1st, 2012. Data from the foetus was not
included in the statistical analysis for survival.
Literature review
In order to identify all publications related to WS, we
first screened PubMed, with the key words: myelo-
kathexis and WHIM. We then checked the bibliography
of each article in order to identify additional references
and to avoid duplicates.
Results
Demographic data
We analyzed data from eight subjects (including 6 males)
presenting WS and one 32 weeks gestational age medic-
ally terminated foetus, originating from four pedigrees
(Table 1). The family trees of the four pedigrees are
shown in the Additional file 2. The median age at the last
follow up was 29 years [p25 8 years – p75 40 years]. De-
finitive WS diagnosis, as defined by the detection of a
CXCR4 mutation or of the characteristic CXCR4 dys-
functions in leukocytes, was established at the median
age of 20 years (SD 25.9) (min 1 year, max 75.6 years),
but for the three cases born in the last ten years this diag-
nosis was made before the age of 2 years, facilitated by
an informative family history in two cases and by more
readily available CXCR4 sequencing. WS-linked symp-
toms first occurred at the median age of 1.3 years (SD
2.32) [min birth- max 5.1 years]. The initial clinical mani-
festations of WS were bacterial infections for five
patients, skin warts for one patient, and isolated neutro-
penia for two patients. Incidence at birth was 0.23
per million births and the 95% confidence interval
limits were 0.0019 – 0.29 per million births.
Bacterial, fungal and mycobacterial infections
Five patients had a history of repeated ENT infections in
childhood, whereas two patients (UPN 55476 and 5780)
reported less than one ENT episode per year, and an-
other patient treated with prophylactic Ig since the age
of 6 months (UPN 5447) reported no ENT episodes.
Severe bacterial infections manifested in seven cases as
mastoiditis, osteoarthritis, nephritis, angiocholitis, bac-
terial adenotidis and armpit, submandibulary or pul-
monary abscesses. The first episode of severe bacterial
infection was recorded at the median age of 10.05 years
[min 1.24 years – max 33.7 years]. However, the fre-
quency of these severe bacterial infections was variable;
three patients experienced less than one episode every
five years. Nevertheless, four patients without a history
of overt pulmonary infections developed COPD and
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Table 1 Demographic, clinical and genetic data of the patients (Continued)
Sputum Candida albicans , P aeruginosa,
E. Coli (40 years)
Intestinal tract C. jejuni, S. aureus ,
C. albicans (40 years)
5446 5-10 years
ENT
M /40.6 years / D Yes
Childhood
HPV 2, 5,23
Yes (−) Stomatitis HSV 1 (24 years) EBV negative
cutaneous T-cell
lymphoma (37 years)Repeated pneumonia, since infancy
complicated by lung abcesses and
chronic bronchiectasis :
S. aureus, H. influenzae , C. albicans,
M. morganii (33 years), S. pneumoniae
(34 years), B. catarrhalis (35 years),










M / 8.6 years / L No No (+) No severe infection Tetralogy of Fallot
ATB: Antibiotic prophylaxis; CXCR4: Chemokine (C-X-C-motif) receptor type 4; D: Death; DNA: deoxyribonucleic acid; EBV: Epstein Barr virus; ENT: Ears nose throat infection; HPV: Human Papillomavirus;





















Beaussant Cohen et al. Orphanet Journal of Rare Diseases 2012, 7:71 Page 6 of 14
http://www.ojrd.com/content/7/1/71bronchiectasis. These were recorded at the age of 8 years
for one patient and after the age of 30 years for three
other patients. These long-term complications were asso-
ciated with late anti-bacterial prophylaxis (including Ig
and antibiotic rotations). Conversely, the only patient so
far free from any infection at the age of 8.6 years was
diagnosed with WS at the age of 6 weeks during a pre-
operative screening, and has since been maintained on
continuous Ig prophylaxis (UPN 5447).
Identified pathogens were Staphylococcus aureus (three
cases), Escherichia coli, Streptococcus pneumoniae and
Haemophilus influenzae (two cases each), Salmonella
typhimurium, Aspergillus glocus, Pseudomonas aeruginosa,
Morganella morganii, Moraxella catarrhalis, Proteus
mirabilis, and Candida albicans (one case each). Atypical
Mycobacterium was observed in two patients. In one case,
mycobacteria infection was limited to the skin and
although the organism was not identified, the referent
physician based the diagnosis on the presence of an
epithelioid granuloma on a skin biopsy and on the sensibil-
ity to rifampicine, isoniazide and pyrazinamid. In the sec-
ond case, the laboratory identifiedMycobacterium gordonae
in the patient’s sputum. Meanwhile, the patient developed
severe liver failure responsible of death. Although the liver
biopsy did not show any granuloma, displaying only a non-
specific inflammation, we hypothesize that the mycobac-
teria infection likely contributed to this liver failure.
HPV-induced warts
Phenotypically, five patients showed varying degrees of
HPV-induced lesions. Skin warts generally first appeared
on hands or feet, but could also affect the face. They devel-
oped for three patients at the ages of 5.1, 5 and 2 years, the
date of onset remaining unknown for the other two
patients. The three patients exempt from warts were aged
75.6, 8.6 and 6.7 years. There was no association between
the age of the skin warts onset and the severity of the wart
proliferation. Extensive pharmaco-resistant cutaneous
verrucosis that reappeared after surgical ablation severely
impaired the quality of life for one patient (UPN 5592).
Besides warts, one male and one female patient
reported anogenital condylomata acuminata (vulva, va-
gina, cervix or rectum mucosa). Vulvar and perianal
lesions were first recorded at the age of 18 years for the
female patient (UPN 5231). In addition, she suffered
from recurrent sporadic genital infections by herpes
viruses since the age of 23 years, despite oral acyclovir
prophylaxis, and aggressive treatment with intravenous
valaciclovir and foscarnet. Later, she exhibited intract-
able multifocal dysplastic HPV-induced lesions despite
several years of repeated cervical conizations and exten-
sive surgery (i.e., vulvectomy, pelvectomy, colostomy,
hysterectomy) and ultimately developed invasive cancer
with an early fatal course at the age of 39.5 years. Themale patient (UPN 5446), whose numerous skin warts
showed HPV serotypes 2, 5 and 23, also presented severe
condylomata acuminata of the ano-rectal area by the
age of 31 years that were surgically removed. We per-
formed HPV serotyping on the anogenital lesions of the
female patient (UPN 5231) for low risk types 6, 11, 44,
53 and 54 and high risk types 45, 31, 18 and 16 and 33,
and only HPV type 6 was detected. This finding was
unexpected considering the lesions’ progression to car-
cinoma. To try to prevent the development of these
mucosal HPV lesions, two of the youngest patients
(UPN 5780 and 5447) were vaccinated at 3 and 5 years
of age with quadrivalent HPV vaccine (designed against
HPV serotypes 6, 11, 16, and 18). Of note, neither patient
has presented warts until now.
Hematological and Immunological parameters
At the time of WS diagnosis, median WBC was
1.050 G/L (p25: 0.7 - p75: 3.7 G/L), ANC was 0.23 G/L
(p25: 0.2 - p75: 0.4 G/L), absolute lymphocyte count
(ALC) was 0.63 G/L (p25: 0.42 - p75: 0.7 G/L), and abso-
lute monocyte count (AMC) was 0.09 (p25: 0.083 - p75:
0.24 G/L). The median hemoglobin (Hb) level was
11.5 g/dL (p25: 10.2 g/dL - p75 12 g/dL) and platelet
count was 201 G/L (p25 172 - p75 223 G/L). Transient
anemia (< 7 g/dL) was observed in two patients, and
transient mild thrombocytopenia (between 50 and
120 G/L) was observed in three patients, without obvi-
ous etiology in both cases. During routine follow-up, a
median of 16 baseline complete blood cell count (CBC)
values per patient was available. For all cases, WBC and
ANC fluctuated with time, without any detectable regu-
lar variation or significant change observed over time,
with the exception of the transiently normalized blood
count values recorded during infectious episodes. The
Additional file 3 illustrates the dynamic variation of the
WBC of four patients at the occasion of sepsis or of
GCSF therapy. Taking into account all the available CBC
recorded during the routine follow up of the patients
(Table 2), with a median number of 17 per patient, the
median WBC was 1.1 G/L (p25: 0.85 - p75: 1.7 G/L), the
ANC was 0.19 G/L (p25: 0.15 - p75: 0.37 G/L), the ALC
was 0.63 G/L (p25: 0.0.42 - p75: 0.7 G/L), and the AMC
was 0.1 (p25: 0.09 - p75: 0.13 G/L). The median Hb level
was 11 g/dL (p25: 10.6 g/dL - p75 12.1 g/dL) and the
median platelet count was 212 G/L (p25 181 - p75
336 G/L). Seven BM smears were available for central
review, all showing rich BM: the granulocytic lineage
represented a total of 36% of BM cells, with 18.5% ma-
ture granulocytes, of which 2.75% were monocytes and
23% were lymphocytes. Examination confirmed myelo-
kathexis in all cases (Figure 1). Four patients were trea-
ted with 5 μg/kg/day GCSF resulting in a significant
increase in the peripheral ANC from a median of 0.340 ×
Table 2 Hematological, immunological features and summary of medical management
UPN ANC ALC AMC PLTs Ig G Ig A Ig M CD3 CD4 CD8 CD19 GCSF
×109/L ×109/L ×109/L ×109/L g/L g/L g/L ×109/L ×109/L ×109/L ×109/L ATB
Ig
Other
5546 0.16 0.38 0.08 223 0.33 0.2 0.1 No GCSF
No ATB
No Ig
5449 0.16 2.08 0.16 452 11.6 (6 mo) 0.12 0.199 1.33 0.89 0.35 0.16 No GCSF
No ATB
No Ig
Foetus NR NR NR NR NR NR NR NR NR NR NR NR
5780 0.16 1.27 0.1 367 2.83* 0 0.53 1 0.77 0.13 0.07 GCSF short course / efficient
No ATB
Early Ig+
5592 1.32 0.3 .021 60 - 0.8 0 0.1 0.02 0.02 0.09 GCSF since age 5 years, on





Warts treated by surgery and
imiquinod with no efficiency
7012 0.22 0.58 0.09 202 9.69 1.89 <0.25 0.67 0.30 0.42 0.01 No GCSF
No ATB
No Ig
5231 0.4 0.17 0.07 212 4.2 0.5 0.4 0.3 0.04 0.04 0 GCSF since age 28 years
/repeated infections despite
GCSF
No ATB but Aciclovir
prophylaxis
Ig +





5447 0.14 1.2 0.1 306 1.8** 1.0 0 0.6 0.54 0.04 0 No GCSF
No ATB
Ig +
ALC: Absolute lymphocyte count; AMC: Absolute Monocyte count; ANC: Absolute neutrophil count; GCSF: Granulocyte colony stimulating factor;
Ig: Immunoglobulin prophylaxis; NR: Non reported; PLTs: Platelets; UPN : Unique patient number; + Present; - Absent **Antibody against vaccine: normal titers.
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109/L under GCSF. AMC and ALC were not significantly
modified (0.11 versus 0.10 G/L and 0.57 versus 0.35 ×
109/L, respectively before and under GCSF treatment).
The total duration of the GCSF treatment was extremely
short in one patient (13 days). The three patients who
received long term GCSF therapy, interrupted treatment
in the absence of significant efficiency to prevent recurrent
infections. Indeed, for patient UPN 5446, despite threeyears of apparent normalization of the ANC consecutive
to daily Lenograstim subcutaneous injections, the number
of infectious pulmonary episodes was not diminished. The
registry recorded similar findings for patients UPN 5231
and 5592.
The total number of lymphocytes was extremely low
among patients with median CD3+ T cells determined at
0.465 × 109/L (SD 0.41) (min 0.1, max 1.33), median CD4+
T cells at 0.25 × 109/L (SD 0.33) (min 0.02, max 0.89),
A B
C D
Figure 1 Bone marrow smears from four patients with myelokathexis, revealing over 50% of neutrophils with abnormal nuclei
encompassing 3 to 5 lobes connected by long thin chromatin filaments, and less than 10% vacuolated mature neutrophils visible on
images A and C. (May-Grunwald-Giemesa stain; original magnification x 1000). A, patient UPN 5780; B, patient UPN 5446; C, patient UPN 5546;
D, patient UPN 5449.
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max 0.42), and median CD19+ B cells at 0.02 × 109/L (SD
0.05) (min 0, max 0.16). Despite the low total lymphocyte
count, the proportion of lymphocyte subsets was apparently
preserved (Table 2).
We evaluated vaccine antigen responses in two
patients. Patient UPN 5780 showed neither anti-tetanus
nor anti-H. influenzae b antibodies (Abs) despite vaccin-
ation 6 months prior, whereas the patient UPN 7012,
who had been vaccinated more than ten years ago, pre-
sented low anti-tetanus Abs, normal anti-pneumococcal
Abs, but no anti-poliovirus Abs. Ig levels were evaluated
in seven patients. IgG levels were mildly low (between
−2 and −3 SD) in two subjects and normal in four sub-
jects. IgA and IgM levels were low in five subjects and
normal in two subjects. Five patients received monthly
Ig replacement therapy including two children since the
diagnosis of WS, and three adults who were also treated
with GCSF because of severe recurrent bacterial infec-
tions. Prophylactic Ig therapy seemed efficient in pre-
venting bacterial infections, particularly in the younger
patients of the cohort, who did not present any further
severe bacterial infection since the introduction of Ig
prophylaxis. Interestingly, three patients who received
neither Ig nor GCSF were free of any bacterial infection.Genetics
We screened CXCR4 mutations for all the patients in-
cluding the foetus: seven patients among three familiespresented mutations of the CXCR4 gene and one patient
had a WT CXCR4 gene (Table 1). We found a new mu-
tation 969_970insG in two related patients, a C1013→G
substitution in three patients from one pedigree, and a
C1000→T substitution in one patient (respectively, in the
CXCR4 proteins G323fsX343, S338X and R334X). These
nonsense or frameshift mutations led to C-tail trunca-
tions of the CXCR4 protein.
Long term outcome and associated pathology
Patient UPN 5446 developed cutaneous T-cell lymphoma
of the right ankle at the age of 37 years uncorrelated with
an Epstein Barr virus (EBV) infection. His father, UPN
7012, presented basal cell carcinoma at the age of
72 years. Two premature deaths were reported in two
siblings respectively at 39.5 and 40.6 years. The causes of
death were metastatic vulvar carcinoma and possible
Mycobacteria-related liver failure. Severe cardiac cono-
truncal malformations were present in two subjects from
unrelated pedigrees with different CXCR4 mutations
(Table 1). The first case was diagnosed with Tetralogy of
Fallot (TOF) at birth and was successfully operated at the
age of two months. The second was diagnosed in utero
with a double aortic arch that led to the medical termin-
ation of the pregnancy at 32 gestational weeks. Fertility
seemed unperturbed in WS patients. One woman gave
birth to two children with non-complicated pregnancies,
had one miscarriage and one terminated pregnancy. The
second woman bore no children. Among affected men,
two of the three adult males had children.
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In this study we describe the French national cohort of
patients with WS, thereby adding 8 patients and 4 pedi-
grees to the 52 previously reported distinct cases origin-
ating from 32 pedigrees (Additional file 1). The genetic
studies performed in 27 pedigrees find that 25 pedigrees
(including 3 from this report) bear CXCR4 mutations.
R334X, the most frequent mutation, is reported in 15
pedigrees (Table 3). The S338X and S339fs342X muta-
tions are respectively detected in 3 and 2 pedigrees,
while the other mutations (E343X, G336X, S341fsX365,
the previously unreported G323fs343X mutation herein
described and the missense mutation E343K) are
reported only once. This survey underlines the extreme
rarity of the WS disease, as the birth ratio observed in
France can be estimated to 0.23 cases per million births.
This incidence rate has been calculated for the period
1990–2006. Nevertheless, we cannot formally exclude
the possibility that there may exist some individuals,
most likely sporadic cases, with milder clinical courses
that do not yet require medical attention and who have
therefore not been included in the registry. This low in-
cidence rate, although never calculated worldwide, is in
accordance with the scarcity of reported cases as shown
in the Additional file 1.
This cohort offers new information about the
hematological and infectious profiles of WS. Interest-
ingly, besides the constant neutropenia and lymphope-
nia, all 8 patients present monocytopenia and half of the
patients present profound monocytopenia below 0.1 G/
L, contrasting with the monocytosis commonly observed
in other congenital neutropenias, such as the elastase
neutrophil expressed (ELANE) syndrome. Of particularTable 3 Literature summary of CXCR4 gene mutations
reported in WHIM Syndrome pedigrees – information










c.969_970insG G323fs343X 1 Present study
c.1000C>T R334X 15 [4,43,59,64–66]
and present
study
c.1006G>T G336X 1 [66]
c.1013C>G S338X 3 [7,21,62] and
present study
c.1016-17delCT S339fsX342 2 [4,63]
c.1021delT S341fsX365 1 [41]
c.1027G>T E343X 1 [4]
c.1027G>A E343K 1 [5]
Wild Type No mutation 2 [7,9,32] and
present study,note, susceptibility to mycobacterial infections may be
added to the infection spectrum of WS. Considering the
monocytopenia and the infectious profile, composed by
pyogenic infections, warts and mycobacteria, WS pre-
sents certain similarities with the Mono-MAC syn-
drome, now identified as the consequence of GATA2
mutations [53,54]. The major phenotypic difference be-
tween the two syndromes is the BM myelokathexis fea-
ture the WS.
We previously reported, in leukocytes derived from
two patients (UPN 5231 and 5446) from pedigree 4 car-
rying a mutated CXCR4 receptor, that the increased Gαi
protein-dependent signaling (e.g. CXCL12-induced
chemotaxis) was associated with the inability of CXCR4
to be uncoupled from G proteins (i.e. desensitized) and
internalized in response to CXCL12 [7], which is in
agreement with other studies (reviewed in [55,56]).
Functional studies could not be assessed in two patients
(UPN 5546 and 5449) from pedigree 1 who did not give
their consent. In this genetic form of WS, impaired
CXCR4 desensitization and internalization resulted from
distal truncations of the receptor’s C-tail thereby remov-
ing potential phosphorylation sites involved in the at-
tenuation process. Interestingly, we also described a
similar pattern of CXCR4 dysfunctions in leukocytes
from one subject carrying a WT CXCR4 open reading
frame and myelokathexis (UPN 5592) with a full WS
phenotype (pedigree 3). This suggests that altered
CXCL12/CXCR4-mediated signaling is a common bio-
logical trait of WS caused by different genetic mutations,
and that for the patients with a WT CXCR4, the genetic
cause(s) may involve an effector protein of the CXCL12/
CXCR4 axis [7]. Later, fibroblasts and EBV-immortalized
B cells derived from this patient were found to display
dysfunctions of G protein coupled receptor kinase 3
(GRK3) pointing to the key role of this kinase in the
regulation of the CXCR4 receptor attenuation [8]. How-
ever, the genetic anomalie(s) causing the GRK3 dysregu-
lation, and the subsequent impairment in CXCR4
inactivation, remain unknown.
Defining WS with certitude is a difficult exercise in
the absence of identified CXCR4 mutations since none
of the terms of the WS acronym (Warts Hypogammaglo-
bulinemia Infections and Myelokathexis) have full sens-
ibility or specificity. Warts concern 58% of the cases in
literature and in agreement with this frequency, five out
of eight cases in our cohort. Hypogammaglobulinemia is
usually very mild with reported levels between −1 and
−2 SD and rarely below. Accordingly, in this cohort,
patients presented variable IgG levels with no cases exhi-
biting frank hypogammaglobulinemia below −3 SD. Al-
though infection susceptibility is on the contrary almost
always present, severe infections are rare. Finally, myelo-
kathexis is not pathognomomic of WS, as it is observed
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glucose 6 phosphatase, catalytic subunit 3 (G6PC3) [57],
CXCR2 loss-of-function mutations [58] or in gastric can-
cer [59]. In addition, for three patients from this study,
BM smears were initially described as showing only an
absence of myeloid blockage, while we identified the typ-
ical multi-lobular nuclei of myelokathexis only at the
time of the central review. Moreover there is one
described WS case with documented CXCR4 mutation
but no myelokathexis (P6 [41]). On the contrary, the
constant panleukopenia and monocytopenia [3,56,60]
are not included in the acronym of the WS. This panleu-
kopenia is also reported in the literature. Indeed, taking
into account all original publications displayed in the
Additional file 1, the median lowest WBC is 1.65 (mean
1.96; p25: 1 - p75: 2.60 G/L), the median lowest ANC is
0.33 (mean of 0.46; p25: 0.13 - p75: 0.75), with constant
lymphopenia and deep monocytopenia (< 0.2 G/l).
According to these observations we now suggest WILM
(Warts, Infections, Leukopenia, and Myelokathexis) as a
new acronym of the syndrome.
To make the definitive diagnosis of WS in the ab-
sence of any CXCR4 mutation, we propose that the as-
sociation of these ‘WILM’ features together with the
gain of CXCR4 function are needed. Under such con-
ditions, two pedigrees with WT CXCR4 have been
described, one originating from Slovenia [9,15], and
one from our survey, for which a GATA2 mutation
was excluded. In addition to these findings, we have
studied two patients with GATA2 mutations who pre-
sented WS-like features (Mycobacterium avium infection,
Warts and Neutropenia) together with an impaired CXCR4
internalization [7,8,61]. This suggests some eventual inter-
play between CXCR4-dependant signalling and GATA2
that could account for the manifestations of neutropenia
and warts of the GATA2 syndrome [62] and beyond, of the
more recently described Serine threonine kinase 4 (STK4)-
linked syndrome [63].
Of particular note was the apparent paradox between
the profoundly altered WBC and the relatively indolent
clinical presentations of WS both in our cohort and in
the literature. Indeed, ANC, ALC (including both T- and
B-cell subpopulations) and AMC are close to those
observed in Severe Combined Immunodeficiency Dis-
ease patients. However, the spectrum of infections pre-
sented by WS patients is rather limited: they only
exhibit a higher susceptibility to bacterial infections from
encapsulated Gram-positive and -negative bacteria,
staphylococcus and mycobacteria. Among the eleven
published cases, for which the bacterial pathogens re-
sponsible for infection were identified (Additional file 1),
Streptococcus pneumonia was reported in seven cases,
Haemophilus influenza in six cases, Staphylococcus
aureus in three cases, and Proteus mirabilis, Clostridiumperfringens and Pseudomonas aeruginosa in one case
each. Finally, apart from two reported cases of herpes
infections, one case of severe chicken pox [13], one case
of rubella and two cases of influenza [5], WS patients
mainly present a particular susceptibility to HPV infec-
tion that manifests as cutaneous (hand/feet/face) and
ano-genital mucosal lesions which abnormally often pro-
gress to cancerous lesions. Although we cannot dismiss
the hypothesis that the WS immunodeficiency eventually
affects anti-HPV immune responses, we rather favor the
possibility that the CXCL12/CXCR4 axis represents a
host susceptibility factor for HPV-infection and asso-
ciated carcinogenic evolution [64]. Low risk HPVs that
infect the mucosa (such as HPV-6 and −11) do not usu-
ally cause cancer in the general population, yet develop
as severe dysplasia and carcinoma in WS patients. It
must further be pointed out that certain types of infec-
tion are not reported in WS such as pulmonar pneumo-
cystosis, zona or severe flu. Thus, the apparent paradox
of WS patients is to exhibit a profoundly altered im-
mune function and yet a limited susceptibility to viral
and bacterial pathogens, with the notable exception of
HPV. This paradox may be explained if we consider that
the disease is mainly related to the neutropenia, which,
in contrast to other congenital neutropenias, is likely
due to an impaired release from the BM that can be
transiently overcome during infection, thus resulting in
normalization of BM cytology and peripheral neutrophil
counts [15,42,43].
The long-term outcome of WS patients from both
our survey and the 52 previously reported patients
indicated five deaths (Figure 2A). No death was
reported before the age of 20 years with the excep-
tion of the medically terminated foetus described in
this study. In addition to the two patients herein
reported, whose deaths were caused by HPV-induced
genital cancer and liver failure, the causes of deaths
were lymphoma in two cases (at the ages of 26 [28]
and 54 years [41]) and bacterial meningitis in one
case (at the age of 31 years [2]). Three other malig-
nancies were reported including one patient who
declared a non-lethal B lymphoma at the age of
31 years followed by a maxillary carcinoma [19], and
another patient who developed a genital cancer of un-
specified etiology at age of 20 years [5]. The overall
cancer risk in this population is estimated to be about
30% by the age of 40 years, with an age of onset be-
yond the third decade (Figure 2B). Genital warts,
which are reported for 23% of the literature cases and
for 28.6% of cases herein described (2 cases), mark a
turning point in the natural course of the disease due
to their likelihood to progress to intractable multi-
focal dysplasia and invasive cancer with an early fatal
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Figure 2 Graphical representation of survival (A) and of the risk of cancer (B) after pooling the 52 published cases of patients with
WHIM Syndrome and the 8 cases reported in this survey.
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cently reported [65], which included the patient UPN 5447,
reported as P3. This association is strengthened by the
herein reported fetus, aborted at 32 gestational weeks due
to a double aortic arch, a cardiac abnormality belonging to
the same group of conotruncal malformations as TOF.
Even though WS is quite rare, the amount of data
collected until now can help to determine the medical
management of afflicted patients. The current standard
therapeutic approach often associates oral antibiotic
prophylaxis, Ig and GCSF. The benefit of Ig prophylaxis
is obvious when proposed early in life, as was the case
for the two youngest patients of this cohort, but less
evident when started later in life, notably after the de-
velopment of permanent lung damage due to previous
infections. The use of GCSF is questionable. Undoubt-
edly, neutropenia is corrected by GCSF, yet infections
do not seem correlated directly to the ANC, and no
chronic stomatitis is reported. In addition, patients in
our cohort withdrew from GCSF due to the lack of effi-
ciency of the treatment against infections and this pat-
tern was equally frequent in the literature [40]. Long
term prophylactic rotational antibiotic therapy is
recorded in two patients with COPD (Table 1) in
addition to their Ig prophylaxis which seemed to lower
the incidence of subsequent pulmonary infection epi-
sodes. However, although prophylactic measures can be
beneficial on bacterial infections they have no impact
on HPV-related disease.
Moreover, for the management of HPV-induced cuta-
neous and genital warts, standard methods such as
cauterization and laser therapy seem relatively inefficient
[34]. Aggressive surgical removal, Interferon or Cidofoviradministration, as well as topical Imiquimod treatments
all proved equally unsatisfying, as lesions tended to re-
appear. This stresses the need for a better understanding
of the physiopathologic mechanisms accounting for the
susceptibility to HPV. Prophylactic quadrivalent HPV
vaccine administration to a WS patient was recently
tested and was associated with protective immunity [25]
suggesting that such a vaccine, if its long-term activity
can be demonstrated, could be used as early prophylactic
treatment for young WS patients and for newly diag-
nosed WS cases. Hematopoietic stem cell transplant-
ation has been proposed once, but with regards to the
natural history of the disease, it seems difficult to
propose a pre-emptive program for all patients, as the
benefit expected by a transplant is to prevent infections
in the third or fourth decade.
We should stress that although the actual management
of WS is prophylactic, treatments that specifically target
the CXCL12/CXCR4 axis are currently being evaluated.
Indeed, two independent phase I clinical trials based on
the acute administration of plerixafor have provided the
pharmacological evidence of the causal role of CXCR4
dysfunctions in the WS-associated panleukopenia. How-
ever, whether such treatment may help to treat or to
prevent HPV lesions, EBV lymphoma or Mycobacteria
infection, remains to be investigated. Moreover, consid-
ering that the management of WS will need efficient and
safe in the long run chronic treatments aimed at nor-
malizing, but not abolishing the CXCR4 signaling, and
because the long-term safety of AMD3100 may be ques-
tioned [66,67], alternative new inhibitory compounds
need to be characterized. The pre-clinical mouse model
of the WS [66,67] will be useful for such analyses.
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Additional file 1: Literature review of 52 published cases of WHIM
syndrome. ** Antibody against vaccine: Normal titers; ALC: Absolute
lymphocyte count; AMC: Absolute Monocyte count; ANC: Absolute
neutrophil count; ATB: Antibiotic prophylaxis; CXCR4: Chemokine (C-X-C-
motif) receptor type 4; EBV: Epstein Barr virus; F: Female, ENT: Ears nose
throat infection; GCSF: Granulocyte colony stimulating factor; GMCSF:
Granulocyte macrophage colony-stimulating factor; HPV: Human
Papillomavirus; Ig: Immunoglobulin prophylaxis; M: Male; NA: Non
applicable; NR: Non reported. UPN: Unique patient number; SP:
Streptococcus pneumoniae; HI: Haemophilus influenzae; SA:
Staphylococcus aureus; PM: Proteus mirabilis; PA: Pseudomonas
aeruginosa; NR: Not reported. + Present; - Absent.
Additional file 2: Family Trees of the four WHIM syndrome
pedigrees described in this study, consistent with autosomal-
dominant inheritance and sporadic cases.
Additional file 3: Sequential variation of blood counts in four
patients illustrating the dynamic of variations of ANC (absolute
neutrophil count), ALC (absolute lymphocyte count) and AMC
(absolute monocyte count), at the occasion of sepsis and
5μg/kg/day Granulocyte colony-stimulating factor (GCSF) therapy.
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